Abstract
Autologous T cells genetically modified with a CD19 chimeric antigen receptor are an effective therapy for children and adults with relapsed or refractory acute lymphoblastic leukemia with initial response rates ranging from 70 to 85%. Unfortunately, about half of these responding patients will subsequently relapse raising the question of whether allogeneic hemopoietic stem cell transplant should be considered as a consolidative therapy. Currently efforts are focused on defining risk factors for relapse to try and develop algorithms predicting which patients may benefit from allogenic transplant.
Original language | English (US) |
---|---|
Article number | 101414 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 35 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2022 |
Externally published | Yes |
Keywords
- Acute lymphoblastic leukemia
- Allogeneic stem cell transplant
- Chimeric antigen receptor
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry